PHARMA CONCLAVE 2018
Strengthening Indian Pharmaceutical
Industry through R&D and Innovation

 

Brochure | Award Nomination Form | Registration Form

09 May, 2018
Hotel The Imperial, New Delhi


      PLATINUM PARTNER                PRINCIPAL SPONSOR              


                                                                          



KNOWLEDGE PARTNER                                                                                                                                                       MEDIA PARTNERS   

                                                                                                         

 




SUPPORTERS 

                                                                                                



                                                                                               

                 








India is a leader in global generic pharmaceuticals manufacturing. It supplies 20% of global generic drugs and is a preferred location for generic drug production. In FY 2016, India 
exported pharmaceutical products worth USD 16.89 billion, with the number expected to reach USD 40 billion by 2020. The country’s pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015‐20 to reach USD 55 billion.



The industry attracted 4.48% of the total FDIs into India from April 2000 to December 2016. The 
cumulative FDI inflows worth USD 14.53 billion were made during the same period.



Although India has strong position in the production of generic pharmaceutical medicines but 
has not yet realized it’s potential to develop a strong, research based pharmaceutical industry that can produce innovative medicines. India has an opportunity to build on its strengths in generics and move up the value chain by enabling innovations and new drug discovery. However, the Indian pharmaceutical industry does not have a strong track record of innovation. A comparison of India with established pharmaceutical innovation leaders‐the US, UK and Japan with countries that have recently moved up the innovation ladder‐South Korea, China and Singapore – shows that there are multiple gaps in the Indian ecosystem. India invests just 0.9% of its GDP (Gross Domestic Product) towards overall research and development compared to an investment of 1.6% in the UK, 1.9% in China, 2.8% in the US and 3.3% and 4% in Japan and South Korea respectively. Availability of funding and overall investments are key concerns that should be discussed.



India is not short on intention and has started to recognize the need to develop an enabling 
ecosystem that supports investment, technology transfer and growth in innovative areas such as biosciences. However, India needs to undertake multiple initiatives across infrastructure, financing, human resources and the legal and regulatory framework to find a place as a preferred destination for pharmaceutical innovation.



To address this subject matter of importance,
ASSOCHAM is organizing “Pharma Conclave 2018: Strengthening Indian Pharmaceutical Industry through R&D and Innovation on May 9, 2018 at Hotel The Imperial, New Delhi.

 

Registration Fees: 

  • Per Delegate: Rs. 3,000/‐  
  • GST will be applicable @ 18%:
  • For more details please contact: 

    Anuj Mathur M: 09810993268 anuj.mathur@assocham.com
    Anshul Gupta M: 09999565047 anshul.gupta@assocham.com
    Vipin Panthri M: 08178386701 vipin.panthri@assocham.com
    Payal Swami M: 08527500385 payal.swami@assocham.com

    Corporate Office
    The Associated Chambers of Commerce and Industry of India
    ASSOCHAM Corporate Office, 5, Sardar Patel Marg
    Chanakyapuri, New Delhi - 110021
    Phone: 46550555 (Hunting Line)
    Fax: 01123017008/9

    Email: assocham@nic.in